Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 May;118(2):215–219. doi: 10.1111/j.1476-5381.1996.tb15389.x

Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits.

M R Soma 1, E Donetti 1, R Seregni 1, L Barberi 1, R Fumagalli 1, R Paoletti 1, A L Catapano 1
PMCID: PMC1909615  PMID: 8735617

Abstract

1. The in vivo antiatherogenic activity of the calcium antagonist, lacidipine, was investigated in two different types of atherosclerotic lesions (proliferative and fatty lesions) induced in rabbits. 2. The proliferative lesion was obtained by positioning a hollow silastic collar around one carotid artery, while aortic fatty lesions were induced by cholesterol feeding. Cholesterol (1%) and lacidipine (1, 3, and 10 mg kg-1) were given daily mixed with standard diet for 8 weeks to White New Zealand rabbits. The intimal hyperplasia (proliferative lesion) was induced 6 weeks after dietary and drug treatment started. 3. The neointimal formation was determined by measuring cross sectional thickness of intimal (I) and medial (M) tissue of fixed arteries. In untreated animals (n = 5), 14 days after collar positioning an intimal hyperplasia was clearly detectable: the arteries with no collar (sham) showed an I/M tissue ratio of 0.03 +/- 0.02, whereas in the carotid with collar the ratio was 0.62 +/- 0.12. In lacidipine-treated animals a significant and dose-dependent effect on proliferative lesions at all three doses tested, was observed. I/M ratios were 0.47 +/- 0.02, 0.40 +/- 0.09, 0.32 +/- 0.02 for doses 1, 3, and 10 mg kg-1 day-1, respectively (P < 0.05). 4. The fatty lesion extent was significantly reduced by lacidipine at the 10 mg kg-1 day-1 dose, although a trend was also observed with lower dosage. 5. These results suggest a direct antiatherosclerotic effect of lacidipine, independent of modulation of risk factors such as hypercholesterolaemia and/or hypertension. Furthermore, the proliferative lesions are apparently more sensitive to lacidipine than are lipid-rich lesions.

Full text

PDF
215

Images in this article

217Figure 2
on p.217

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernini F., Bellosta S., Didoni G., Fumagalli R. Calcium antagonists and cholesteryl ester metabolism in macrophages. J Cardiovasc Pharmacol. 1991;18 (Suppl 10):S42–S45. [PubMed] [Google Scholar]
  2. Bernini F., Catapano A. L., Corsini A., Fumagalli R., Paolétti R. Effects of calcium antagonists on lipids and atherosclerosis. Am J Cardiol. 1989 Nov 7;64(17):129I–134I. doi: 10.1016/0002-9149(89)90970-3. [DOI] [PubMed] [Google Scholar]
  3. Bernini F., Corsini A., Raiteri M., Soma M. R., Paoletti R. Effects of lacidipine on experimental models of atherosclerosis. J Hypertens Suppl. 1993 Mar;11(1):S61–S66. doi: 10.1097/00004872-199303001-00011. [DOI] [PubMed] [Google Scholar]
  4. Carew T. E., Schwenke D. C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A. 1987 Nov;84(21):7725–7729. doi: 10.1073/pnas.84.21.7725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Corsini A., Quarato P., Raiteri M., Paubert-Braquet M., Nguyen G., Picquot S., Bourgain R. H., Fumagalli R., Paoletti R. Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol Res. 1993 May-Jun;27(4):299–307. doi: 10.1006/phrs.1993.1030. [DOI] [PubMed] [Google Scholar]
  6. Daugherty A., Rateri D. L., Schonfeld G., Sobel B. E. Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br J Pharmacol. 1987 May;91(1):113–118. doi: 10.1111/j.1476-5381.1987.tb08989.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Daugherty A., Zweifel B. S., Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol. 1989 Oct;98(2):612–618. doi: 10.1111/j.1476-5381.1989.tb12635.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Erikson U., Nilsson S., Stenport G. Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery. Am J Cardiol. 1988 Jul 25;62(3):44B–47B. doi: 10.1016/s0002-9149(88)80050-x. [DOI] [PubMed] [Google Scholar]
  9. Henry M. Primary nursing in long-term care: is it economically feasible? J Gerontol Nurs. 1990 Oct;16(10):12–15. doi: 10.3928/0098-9134-19901001-05. [DOI] [PubMed] [Google Scholar]
  10. Jackson C. L., Schwartz S. M. Pharmacology of smooth muscle cell replication. Hypertension. 1992 Dec;20(6):713–736. doi: 10.1161/01.hyp.20.6.713. [DOI] [PubMed] [Google Scholar]
  11. Keogh A. M., Schroeder J. S. A review of calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol. 1990;16 (Suppl 6):S28–S35. [PubMed] [Google Scholar]
  12. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928–5931. doi: 10.1073/pnas.84.16.5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kunjara-Na-Ayudhya R., Thomson A. B., Kappagoda C. T. Effect of isradipine on the formation and regression of fatty streaks in cholesterol fed rabbits. Cardiovasc Res. 1994 Jul;28(7):1089–1095. doi: 10.1093/cvr/28.7.1089. [DOI] [PubMed] [Google Scholar]
  14. Lichtlen P. R., Nellessen U., Rafflenbeul W., Jost S., Hecker H. International nifedipine trial on antiatherosclerotic therapy (INTACT). Cardiovasc Drugs Ther. 1987;1(1):71–79. doi: 10.1007/BF02125836. [DOI] [PubMed] [Google Scholar]
  15. Lichtor T., Davis H. R., Vesselinovitch D., Wissler R. W., Mullan S. Suppression of atherogenesis by nifedipine in the cholesterol-fed rhesus monkey. Appl Pathol. 1989;7(1):8–18. [PubMed] [Google Scholar]
  16. Nayler W. G. Calcium channels and their involvement in cardiovascular disease. Biochem Pharmacol. 1992 Jan 9;43(1):39–46. doi: 10.1016/0006-2952(92)90658-6. [DOI] [PubMed] [Google Scholar]
  17. Nayler W. G. Pharmacological aspects of calcium antagonism. Short term and long term benefits. Drugs. 1993;46 (Suppl 2):40–47. doi: 10.2165/00003495-199300462-00009. [DOI] [PubMed] [Google Scholar]
  18. Nomoto A., Mutoh S., Hagihara H., Yamaguchi I. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis. 1988 Aug;72(2-3):213–219. doi: 10.1016/0021-9150(88)90083-4. [DOI] [PubMed] [Google Scholar]
  19. Paoletti R., Bernini F., Fumagalli R., Allorio M., Corsini A. Calcium antagonists and low density lipoprotein receptors. Ann N Y Acad Sci. 1988;522:390–398. doi: 10.1111/j.1749-6632.1988.tb33380.x. [DOI] [PubMed] [Google Scholar]
  20. Parmley W. W. Calcium channel blockers and atherogenesis. Am J Med. 1987 Mar 30;82(3B):3–8. doi: 10.1016/0002-9343(87)90204-x. [DOI] [PubMed] [Google Scholar]
  21. Popma J. J., Califf R. M., Topol E. J. Clinical trials of restenosis after coronary angioplasty. Circulation. 1991 Sep;84(3):1426–1436. doi: 10.1161/01.cir.84.3.1426. [DOI] [PubMed] [Google Scholar]
  22. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  23. Schmitz G., Robenek H., Beuck M., Krause R., Schurek A., Niemann R. Ca++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. I. Characterization of cellular lipid metabolism. Arteriosclerosis. 1988 Jan-Feb;8(1):46–56. doi: 10.1161/01.atv.8.1.46. [DOI] [PubMed] [Google Scholar]
  24. Soma M. R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., Paoletti R. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 1993 Apr;13(4):571–578. doi: 10.1161/01.atv.13.4.571. [DOI] [PubMed] [Google Scholar]
  25. Soma M. R., Donetti E., Parolini C., Sirtori C. R., Fumagalli R., Franceschini G. Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res. 1995 Mar;76(3):405–411. doi: 10.1161/01.res.76.3.405. [DOI] [PubMed] [Google Scholar]
  26. Soma M. R., Parolini C., Donetti E., Fumagalli R., Paoletti R. Inhibition of isoprenoid biosynthesis and arterial smooth-muscle cell proliferation. J Cardiovasc Pharmacol. 1995;25 (Suppl 4):S20–S24. [PubMed] [Google Scholar]
  27. Stein O., Stein Y. Effect of verapamil on cholesteryl ester hydrolysis and reesterification in macrophages. Arteriosclerosis. 1987 Nov-Dec;7(6):578–584. doi: 10.1161/01.atv.7.6.578. [DOI] [PubMed] [Google Scholar]
  28. Waters D., Lespérance J. Calcium channel blockers and coronary atherosclerosis: from the rabbit to the real world. Am Heart J. 1994 Dec;128(6 Pt 2):1309–1316. doi: 10.1016/0002-8703(94)90253-4. [DOI] [PubMed] [Google Scholar]
  29. Weinstein D. B., Heider J. G. Antiatherogenic properties of calcium antagonists. State of the art. Am J Med. 1989 Apr 17;86(4A):27–32. doi: 10.1016/0002-9343(89)90186-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES